FDA Approves New Drug for VWD
Horizons in Hemophilia, April 2010
By Leigh Carpenter, RPh, Chief Pharmacist
Xanodyne Pharmaceuticals, Inc. has announced FDA approval for Lysteda, a tablet form of tranexamic acid that is used to treat heavy menstrual bleeding. Previously, this drug was only available in the United States as an injectible drug (Cyklokapron). This approval represents an important new non-hormonal treatment option for women suffering from heavy menstrual bleeding, a very common symptom of vWD. The company has not announced a release date for the product. More information will follow as soon as we receive it; be sure to check www.hog.org or www.beaconpharmacy.net for the announcement. Xanodyne also manufacturers Amicar syrup and tablets.